Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1

Interventions

Bevacizumab 5Leucovorin 4Irinotecan 4Fluorouracil 4Oxaliplatin 3Capecitabine 3Drug Therapy 2trifluridine tipiracil drug combination 1romiplostim 1napabucasin 1entecavir 1encorafenib 1durvalumab 1apatinib 1abelacimab 1Sunitinib 1Specimen Handling 1Sodium Chloride 1S-1 plus cisplatin 1Radiosurgery 1Palonosetron 1Oviposition 1Nutrition Assessment 1Nucleotides 1Methylphenidate 1Memantine 1Melatonin 1Magnetic Resonance Spectroscopy 1MAA868 1Levoleucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Gastrointestinal Neoplasms × IDRX-42 × Clear all
NCT07218926 2026-05-27

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

GlaxoSmithKline

Phase 3 Recruiting
450 enrolled
GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡